Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.17) by 47.06 percent. The company reported quarterly sales of $47.651 million which missed the analyst consensus estimate of $49.155 million by 3.06 percent. This is a 22.76 percent increase over sales of $38.815 million the same period last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
如果下載按鈕點擊無跳轉，請點擊右上角菜單選擇 “在瀏覽器打開”